Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30426642 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRABCG2HPGDTDP1 | |
| SCHEMBL17518840 | 0.89 | ALDH1A1 (0.47) | ALDH1A1TSHRABCG2HPGDTDP1 | |
| SCHEMBL2593503 | 0.88 | MCL1 (0.50) | ALDH1A1TSHRABCG2HPGDTDP1 | |
| SCHEMBL16619850 | 0.86 | ALDH1A1 (0.59) | ALDH1A1TSHRHPGDTDP1TRIM24 | |
| SCHEMBL96635 | 0.86 | ALDH1A1 (0.59) | ALDH1A1TSHRHPGDTDP1TRIM24 | |
| SCHEMBL9859402 | 0.84 | ALDH1A1 (0.43) | ALDH1A1TSHRABCG2HPGDTDP1 | |
| SCHEMBL2648356 | 0.84 | ALDH1A1 (0.54) | ALDH1A1TSHRABCG2HPGDTDP1 | |
| Hydrochloric Acid SCHEMBL23711567 | 0.84 | ALDH1A1 (0.57) | ALDH1A1TSHRHPGDTDP1TRIM24 | |
| SCHEMBL2680807 | 0.83 | ALDH1A1 (0.45) | ALDH1A1TSHRABCG2HPGDTDP1 | |
| SCHEMBL668507 | 0.83 | TUBB4A (0.51) | ALDH1A1TSHRABCG2HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124173-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250304533-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12419962-B2 | Quinazolines, pharmaceutical compositions, and therapeutic applications | BIOTHERYX, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12410128-B1 | Therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12365922-B2 | Allele editing and applications thereof | UNIVERSITÄT BASEL (CH) | 2025-07-22 | — | — | US | disclosed |
| WO-2025101939-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-109715803-B | Allele editing and uses thereof | 巴塞尔大学 | 2023-07-07 | — | — | CN | disclosed |
| US-20230193320-A1 | ALLELE EDITING AND APPLICATIONS THEREOF | UNIVERSITÄT BASEL (CH) | 2023-06-22 | — | — | US | disclosed |
| WO-1995024200-A1 | METHOD FOR TREATING 5HT2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1995-09-14 | — | — | WO | disclosed |
| US-5434151-A | Treatment of immune and inflammatory disorders, aryl substituted tetrahydrofurans, tetrahydrothiophenes, cyclopentanes, pyrrolidines | CYTOMED, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0650485-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994023720-A1 | TETRAHYDRO-BETA-CARBOLINES | ELI LILLY AND COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
| US-5358938-A | 2,5-Diaryl tetrahydrofurans, tetrahydrothiophenes, 1,3-cyclo-pentanes and pyrrolidines | CYTOMED, INC. (US) | 1994-10-25 | — | — | US | disclosed |
| EP-0620222-A2 | Tetrahydro-beta-carbolines | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| EP-0574510-A4 | NEOLIGNAN DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS AND 5-LIPOXYGENASE INHIBITORS | INNOVATIVE TECH CENTER (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1994001430-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| EP-0574510-A1 | NEOLIGNAN DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS AND 5-LIPOXYGENASE INHIBITORS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-12-22 | — | — | EP | disclosed |
| WO-1992015294-A1 | NEOLIGNAN DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS AND 5-LIPOXYGENASE INHIBITORS | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304533-A1 | THERAPEUTIC ALKALOID COMPOUNDS | HTR3B, MTNR1B, PNMT | ALDH1A1 2227/4885TSHR 4064/4885ABCG2 341/4885 |
| US-12419962-B2 | Quinazolines, pharmaceutical compositions, and therapeutic applications | RAB1A, SOS1, IQGAP1 | ALDH1A1 2378/4885TSHR 4233/4885ABCG2 204/4885 |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | ALDH1A1 2378/4885TSHR 4233/4885ABCG2 204/4885 |
| US-20260124173-A1 | THERAPEUTIC ALKALOID COMPOUNDS | ADRA1B, HTR1B, ADRB1 | ALDH1A1 903/4885TSHR 194/4885ABCG2 158/4885 |
| US-12410128-B1 | Therapeutic alkaloid compounds | HTR3B, MTNR1B, PNMT | ALDH1A1 2227/4885TSHR 4064/4885ABCG2 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.